News

Shares of Grifols (NASDAQ: GRFS) were up 11.1% on Tuesday afternoon, after being up as much as 13.1% earlier in the day. The pharmaceutical company, which makes plasma-derived medicines, released

Axsome Therapeutics (NASDAQ: AXSM) stood out last year. The biotech began selling its first two products: Sunosi, a sleep disorder drug it acquired from Jazz Pharmaceuticals; and Auvelity, an

Shares of the developmental gene-editing company CRISPR Therapeutics (NASDAQ: CRSP) were up by 12.4% on sky-high volume as of 1:46 p.m. ET Tuesday afternoon. The big gain came in response to the bio

The biggest disappointment from AT&T's (NYSE: T) first-quarter earnings report was its dismal free cash flow.

Free cash flow is extremely important for AT&T investors, many of whom look for the

The struggles of contract drugmaker Catalent (NYSE: CTLT) continued on Monday, leading to a big sell-off in the company's stock. Investors were heavily discouraged by their company's latest update

Image source: The Motley Fool.

Axsome Therapeutics (NASDAQ: AXSM)Q1 2023 Earnings CallMay 08, 2023, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

Monday was a relatively quiet day on Wall Street, with most major benchmarks seeing modest losses at midday. With key inflation and other economic data coming in the near future, investors are

Eli Lilly (NYSE: LLY) and Merck (NYSE: MRK) have seen their shares rise by over 17% and 5%, respectively, this year while the S&P 500 Health Care Sector Index has dropped 1.7%. What's interesting

If you can buy high-quality dividend stocks when other investors sour on them, you can plant the seeds for robust returns in the future. And that's exactly why it might be worth buying shares of

Dividend growth investing revolves around selecting only the most reliable businesses for your portfolio. This can be measured by consecutive years of dividend growth.

With 51 consecutive years of

Most Americans don't have to wait until they're retired to know that Social Security benefits won't be enough to maintain their current lifestyle. If they pay any attention to retirement planning

Shares of Summit Therapeutics (NASDAQ: SMMT) were up by 61.4% for the week as of late Friday afternoon, according to data provided by S&P Global Market Intelligence. The healthcare stock, which

Fears of a coming recession are probably about as high right now as they have been over the past year. That's because the U.S. Federal Reserve recently predicted an economic downturn would descend

Going, going, gone? That could be the question that Novocure (NASDAQ: NVCR) investors are asking these days. Shares of the oncology company plunged 56% in 2021. The stock slid 2% lower last year

Shares of Karyopharm Therapeutics (NASDAQ: KPTI) were down more than 26% Thursday afternoon after the biotech company released first-quarter earnings and updated its guidance. The stock fell to its

Pfizer (NYSE:PFE) confirmed this week what everyone has been expecting. COVID-19 vaccine sales are falling drastically. The company reported a 77% drop in Comirnaty sales in the first quarter

Regeneron Pharmaceuticals (NASDAQ: REGN), a large-cap biotechnology company, is under heavy pressure today. Specifically, the biotech's stock was down by an unsightly 6.5% on heavy volume as of

Image source: The Motley Fool.

Karyopharm Therapeutics (NASDAQ: KPTI)Q1 2023 Earnings CallMay 04, 2023, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

Image source: The Motley Fool.

Zoetis (NYSE: ZTS)Q1 2023 Earnings CallMay 04, 2023, 8:30 a.m. ET

Operator

Continue reading

Source Fool.com